Browsing Tag
South San Francisco
5 posts
Shenandoah Therapeutics appoints Steve Worland CEO as BCL6 cancer program nears IND studies
Shenandoah Therapeutics has appointed biotechnology veteran Steve Worland as chief executive officer, with co-founder Isabella Graef moving into the chief scientific officer role. The leadership change comes as the company's BCL6-targeting oncology program approaches IND-enabling studies, creating an important test of its transcriptional and epigenetic drug discovery platform.
Aligos receives $25m Amoytop payment as China HBV catalyst strengthens
Aligos receives $25 million from Amoytop as China grants breakthrough status to its HBV drug. Read how the deal reshapes ALGS cash runway and strategy.
QNCX: What does the reverse merger hunt at Quince Therapeutics mean for shareholders after the NEAT trial collapse?
Quince Therapeutics (Nasdaq: QNCX) has no pipeline and a September Nasdaq deadline. Here's what the reverse merger hunt actually means for retail investors watching this stock.
The new engine of drug discovery? Inside Thermo Fisher Scientific’s cryo-EM hub in the Bay Area
Thermo Fisher Scientific opens a cryo-EM drug discovery center in South San Francisco to accelerate structural biology research. Discover why this matters for pharma.
Novo Nordisk and Septerna forge $2.2bn GPCR deal to develop oral therapies for obesity and diabetes
Novo Nordisk partners with Septerna in a $2.2B deal to develop oral GPCR therapies for obesity and diabetes. Explore the full stock sentiment and deal impact.